Weight loss drug 'increases depression risk'

Advice to assess obese patients for depression before being given weight loss drug rimonabant has been reiterated following further evidence that the drug increases the risk of depression and anxiety.

It follows the findings of a meta-analysis of four trials carried out by Danish researchers that showed patients given rimonabant were 2.5 times more likely to stop treatment because of depression than those on placebo.

Patients were also three times more likely to quit treatment because of anxiety.

The four trials included a total of 4,105 patients who were randomly assigned 20mg rimonabant daily or placebo. Any patients suffering from depressed mood at baseline were excluded from the trial.

Patients given the drug had 4.7kg greater weight loss after the first year than those on placebo.

However, the rate of serious adverse events was 40 per cent higher in the treatment group.

In July this year, the EMEA said rimonabant should be contraindicated in those with major depression or those on antidepressants.

Dr David Haslam, clinical director of the National Obesity Forum, said GPs need to consider these contraindications before prescribing rimonabant.

A spokeswoman for manufacturer Sanofi-Aventis said it ‘has actively sought to ensure that treatment is prescribed to the right patient’.

rachel.liddle@haymarket.com


www.thelancet.com

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Government outlines PPE supply plans as GPs remain in dark over reimbursement

Government outlines PPE supply plans as GPs remain in dark over reimbursement

The government has outlined plans to provide 'an uninterrupted supply' of PPE during...

Four in five GPs report heavy workload as COVID-19 second wave builds

Four in five GPs report heavy workload as COVID-19 second wave builds

Four in five GPs say their practice is currently facing levels of workload that are...

Medeconomics Live: Bringing you the latest in practice management thinking

Medeconomics Live: Bringing you the latest in practice management thinking

The one-day, virtual Medeconomics Live conference aims to provide essential insights...

First COVID-19 jabs to target care home residents and staff under new JCVI advice

First COVID-19 jabs to target care home residents and staff under new JCVI advice

Older adults living in care homes and staff working there will be first to receive...

GPs unable to veto virtual fitness to practise hearings during pandemic

GPs unable to veto virtual fitness to practise hearings during pandemic

GPs facing fitness to practise investigations during the COVID-19 pandemic will be...

Government rejects major NHSPS overhaul - but changes 'could ease GP service charge disputes'

Government rejects major NHSPS overhaul - but changes 'could ease GP service charge disputes'

A government review has rejected calls for a major overhaul of an NHS Property Services...